Phase 2 vs Phase 3 — Dermatology Deal Valuation Comparison
Market Analysis
The Phase 2 to Phase 3 transition in dermatology represents a significant value inflection point. Phase 3 deals carry a median total deal value of $4.6B compared to $2.1B at Phase 2, a 119% premium reflecting clinical de-risking. Upfront payments increase from $393M to $1.3B.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the deal value premium from Phase 2 to Phase 3 in dermatology?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating